menu
    • menu

    Company profile for Accent Therapeutics

    NEW Drugs in Dev: 4
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Accent is building a highly collaborative team of experienced drug developers, all keenly focused on building the bridge from extraordinary science to life-changing therapies for patients.Our people are Accent. Their rigor, patient focus, resolute purpose, adventurous spirits and contagious enthusiasm are what drive us forward.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Accent TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1050 Waltham St., Suite 201 Lexington, MA 02421
    Telephone
    Telephone
    +339-970-7400
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.accenttx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/accenttherapeutics/?originalSubdomain=in
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/accent_tx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CGT Asia

    Not Confirmed

    envelop Contact Supplier

    CGT Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Accent Halts DHX9 Inhibitor Trial Over Adverse Events
    Accent Halts DHX9 Inhibitor Trial Over Adverse Events

    26 Feb 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/accent-halts-solid-tumor-trial-over-adverse-events-pivots-other-lead-cancer-program

    FIERCE BIOTECH
    26 Feb 2026
    Share Share
    Accent Therapeutics Leverages Inocras Platforms in ATX-295 Study
    Accent Therapeutics Leverages Inocras Platforms in ATX-295 Study

    28 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260128013399/en/Accent-Therapeutics-to-Utilize-Inocras-CancerVision-and-MRDVision-Platforms-in-Phase-12-ATX-295-Clinical-Study

    BUSINESSWIRE
    28 Jan 2026
    Share Share
    Accent Therapeutics Unveils Preclinical Data On ATX-295
    Accent Therapeutics Unveils Preclinical Data On ATX-295

    22 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/accent-therapeutics-presents-new-preclinical-data-on-lead-clinical-programs-atx-295-and-atx-559-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-302589136.html

    PR NEWSWIRE
    22 Oct 2025
    Share Share
    Boehringer Acquires Oncology Program From Accent Therapeutics
    Boehringer Acquires Oncology Program From Accent Therapeutics

    08 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/boehringer-ingelheim-obtains-novel-preclinical-oncology-program-from-accent-therapeutics-302576299.html

    PR NEWSWIRE
    08 Oct 2025
    Share Share
    Accent Therapeutics Trial in Progress Poster for ATX-559 at 2025
    Accent Therapeutics Trial in Progress Poster for ATX-559 at 2025

    22 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/accent-therapeutics-announces-trial-in-progress-poster-for-first-in-human-study-of-atx-559-at-2025-asco-annual-meeting-302461098.html

    PR NEWSWIRE
    22 May 2025
    Share Share
    Accent Therapeutics Shows Data on ATX-559 and ATX-295 at AACR 2025
    Accent Therapeutics Shows Data on ATX-559 and ATX-295 at AACR 2025

    28 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/accent-therapeutics-presents-data-supporting-therapeutic-potential-of-first-in-class-dhx9-inhibitor-atx-559-and-novel-kif18a-inhibitor-atx-295-at-the-aacr-annual-meeting-2025-302438756.html

    PR NEWSWIRE
    28 Apr 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search